Is There a COVID-Related Wound?
A variety of skin lesions have been described with Coronavirus infection, also called COVID-19 or SARS-CoV-2, and this post explores whether there is a link between COVID and wounds. Understanding of this disease is still in the early stages, and it is unclear whether these skin lesions are the result of comorbidities or coinfection with other agents, or whether COVID-19 is actually responsible. A search of the world literature reveals the following skin issues with COVID: Acral erythema (redness and swelling of the hands and feet) with vesicles and pustules. This is similar to chilblains – a condition associated with exposure to cold and manifesting in painful inflammation of small blood vessels in the skin. Urticarial lesions. This is similar to hives and accompanied by severe itching. Maculopapular eruptions. These are flat and raised lesions of the skin. Vesicular eruptions. This is characterized by small fluid filled sacs that may be clear, white, yellow, or mixed with blood. Livedo-like lesions, sometimes with purpura or necrosis. The term ‘livedo’ refers to a net-like or mottled appearance. Purpura refers to the appearance of a bruise, similar to a Deep Tissue Injury (DTI) pressure injury. This pattern is seen in older patients with more severe disease. Of these, the livedo lesion with purpura or necrosis is of greatest concern for potential wound development, as biopsies demonstrate microthrombi (small clot...
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Publication date: Available online 10 October 2020Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): N.G. Shah, B.C. Wible, J.A. Paulisi, M. Zaki, P. Lamparello, A. Sista, M. Sadek, G.R. Jacobowitz, T.S. Maldonado
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
More News: Anemia | Coronavirus | COVID-19 | Decubitus Ulcer (bed sore) | Dermatology | Diabetes | Diabetic Ulcers | Endocrinology | Geriatrics | Hives | Hospitals | Laboratory Medicine | Liver | Nutrition | Pressure Sores | Respiratory Medicine | SARS | Skin | Skin Biopsy | Thrombosis | Toxicology | UK Health | Urology & Nephrology